57 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
Print name of Spouse
Signature of Spouse
(if the Warrant Shares are held in joint name or are community property)
B. THIS SECTION B
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
of DCCR, if and when approved, by patients, the medical community, and third-party payers;
the regulatory approval pathway that we pursue for DCCR … believe such product candidates, if approved, will provide a clinical utility or benefit to patients;
whether the medical community accepts
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
;
acceptance of DCCR, if and when approved, by patients, the medical community, and third-party payers;
the regulatory approval pathway that we … providers believe such product candidates, if approved, will provide a clinical utility or benefit to patients;
whether the medical community accepts
8-K
EX-99.1
pg99urzwf45yh5zwxz30
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
5aoi19kt
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-10.1
hxjmqe1 id
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
424B5
annkldzm96k
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
gd8e52n7yd yvtjae32a
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
aosgbjclrbi
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
myp c31apggzoafn
15 Apr 21
Other Events
12:00am
8-K
EX-99.1
rfupz0ajo8xewu255
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
og8x8vtn048apqkx
15 Apr 21
Other Events
12:00am